MedTrace Logo

Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.

NCT03869476 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2024-12-30

No results posted yet for this study

Summary

Prospective study for the development of a non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis.

Conditions

  • Myeloproliferative Disorder
  • Essential Thrombocythemia
  • Primary Myelofibrosis, Prefibrotic Stage
  • Primary Myelofibrosis, Fibrotic Stage

Interventions

DIAGNOSTIC_TEST

Non-invasive diagnosis score

* spleen fibrosis by elastography * plasma cytokines levels * mutationnal landscape by NGS * CD34 circulating cells

Sponsors & Collaborators

  • University Hospital, Angers

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-30
Primary Completion
2024-01-30
Completion
2024-01-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03869476 on ClinicalTrials.gov